Vaccine · 2026
Protection of Omicron XBB.1.5 vaccine, previous infection, and their induced neutralizing antibodies against symptomatic SARS-CoV-2 infection during Omicron KP.3 wave.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yamamoto Shohei, Matsuda Kouki, Maeda Kenji, Mizoue Tetsuya, Horii Kumi, Oshiro Yusuke, Inamura Natsumi, Nemoto Takashi, Akahori Yuichi, Takeuchi Junko S, Konishi Maki, Sugiura Wataru, Ohmagari Norio
Аннотация
BACKGROUND: Data are limited on the protection of Omicron XBB.1.5 vaccine, previous infection, and their induced neutralizing antibodies against Omicron KP.3 infection.
METHODS: Among 1826 tertiary hospital staff in Tokyo who had received three or more doses of COVID-19 mRNA vaccines and provided blood samples in June 2024, we prospectively examined the associations of XBB.1.5 vaccination and previous infection (classified by the timing of the last infection as pre-Omicron XBB, Omicron XBB, or Omicron JN.1 waves) with the risk of symptomatic SARS-CoV-2 infection during the Omicron KP.3 wave (June to September 2024). In a nested case-control analysis, we compared pre-infection live-virus KP.3.3-neutralizing antibody titers between cases and 1: 1 propensity-score matched controls.
RESULTS: XBB.1.5 vaccination was not associated with measurable protection against symptomatic infection (4%, 95% CI, -88 to 51). Previous infection conferred protection that increased with its recency: 26% (95% CI, -26 to 56) for pre-Omicron XBB, 44% (95% CI, 2 to 68) for Omicron XBB, and 89% (95% CI, 52 to 97) for Omicron JN.1 waves. Pre-infection KP.3.3-neutralizing titers tended to be lower in cases than in matched controls (GMT ratio 0.68, 95% CI, 0.35 to 1.33); KP.3.3-neutralizing activity was only modestly elevated by XBB.1.5 vaccination but markedly higher after recent JN.1 infection.
CONCLUSIONS: During the Omicron KP.3 wave, when an updated vaccine was unavailable, XBB.1.5 vaccination administered approximately 7 months earlier conferred no measurable neutralizing activity or protection against symptomatic KP.3 infection. Previous SARS-CoV-2 infection, particularly recent JN.1-wave infection, affords substantial neutralizing titers and protection.
METHODS: Among 1826 tertiary hospital staff in Tokyo who had received three or more doses of COVID-19 mRNA vaccines and provided blood samples in June 2024, we prospectively examined the associations of XBB.1.5 vaccination and previous infection (classified by the timing of the last infection as pre-Omicron XBB, Omicron XBB, or Omicron JN.1 waves) with the risk of symptomatic SARS-CoV-2 infection during the Omicron KP.3 wave (June to September 2024). In a nested case-control analysis, we compared pre-infection live-virus KP.3.3-neutralizing antibody titers between cases and 1: 1 propensity-score matched controls.
RESULTS: XBB.1.5 vaccination was not associated with measurable protection against symptomatic infection (4%, 95% CI, -88 to 51). Previous infection conferred protection that increased with its recency: 26% (95% CI, -26 to 56) for pre-Omicron XBB, 44% (95% CI, 2 to 68) for Omicron XBB, and 89% (95% CI, 52 to 97) for Omicron JN.1 waves. Pre-infection KP.3.3-neutralizing titers tended to be lower in cases than in matched controls (GMT ratio 0.68, 95% CI, 0.35 to 1.33); KP.3.3-neutralizing activity was only modestly elevated by XBB.1.5 vaccination but markedly higher after recent JN.1 infection.
CONCLUSIONS: During the Omicron KP.3 wave, when an updated vaccine was unavailable, XBB.1.5 vaccination administered approximately 7 months earlier conferred no measurable neutralizing activity or protection against symptomatic KP.3 infection. Previous SARS-CoV-2 infection, particularly recent JN.1-wave infection, affords substantial neutralizing titers and protection.